Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone908-809-1300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$263.70 million
Profitability
Miscellaneous
Employees466
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions
What is Osmotica Pharmaceuticals' stock symbol?
Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."
How were Osmotica Pharmaceuticals' earnings last quarter?
Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) released its earnings results on Thursday, August, 8th. The company reported $0.02 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.04) by $0.06. The company earned $57.53 million during the quarter, compared to the consensus estimate of $57.90 million. Osmotica Pharmaceuticals had a negative return on equity of 32.14% and a negative net margin of 97.91%. View Osmotica Pharmaceuticals' Earnings History.
When is Osmotica Pharmaceuticals' next earnings date?
What price target have analysts set for OSMT?
4 equities research analysts have issued 1 year price targets for Osmotica Pharmaceuticals' stock. Their predictions range from $10.00 to $17.00. On average, they anticipate Osmotica Pharmaceuticals' share price to reach $13.00 in the next year. This suggests a possible upside of 186.3% from the stock's current price. View Analyst Price Targets for Osmotica Pharmaceuticals.
What is the consensus analysts' recommendation for Osmotica Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Osmotica Pharmaceuticals.
Has Osmotica Pharmaceuticals been receiving favorable news coverage?
Press coverage about OSMT stock has trended somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Osmotica Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Osmotica Pharmaceuticals.
Are investors shorting Osmotica Pharmaceuticals?
Osmotica Pharmaceuticals saw a decrease in short interest in the month of September. As of September 15th, there was short interest totalling 163,400 shares, a decrease of 21.4% from the August 15th total of 207,900 shares. Based on an average daily trading volume, of 108,700 shares, the short-interest ratio is currently 1.5 days. Currently, 2.3% of the shares of the company are sold short. View Osmotica Pharmaceuticals' Current Options Chain.
Who are some of Osmotica Pharmaceuticals' key competitors?
Some companies that are related to Osmotica Pharmaceuticals include Spectrum Pharmaceuticals (SPPI), Odonate Therapeutics (ODT), TherapeuticsMD (TXMD), Amneal Pharmaceuticals (AMRX), ANI Pharmaceuticals (ANIP), Phibro Animal Health (PAHC), Achillion Pharmaceuticals (ACHN), ZEALAND PHARMA/S (ZEAL), Eagle Pharmaceuticals (EGRX), Athenex (ATNX), G1 Therapeutics (GTHX), Dova Pharmaceuticals (DOVA), Cara Therapeutics (CARA), Axsome Therapeutics (AXSM) and CannTrust (CNTTF).
What other stocks do shareholders of Osmotica Pharmaceuticals own?
Who are Osmotica Pharmaceuticals' key executives?
Osmotica Pharmaceuticals' management team includes the folowing people:
- Mr. Brian A. Markison, Chairman, Pres & CEO (Age 60)
- Mr. Andrew J. Einhorn, Chief Financial Officer (Age 59)
- Dr. Tina Marie deVries, Exec. VP of R&D (Age 58)
- Mr. James D. Schaub, Exec. VP & COO (Age 37)
- Mr. Christopher A. Klein, Gen. Counsel & Sec. (Age 55)
When did Osmotica Pharmaceuticals IPO?
(OSMT) raised $58 million in an initial public offering on Thursday, October 18th 2018. The company issued 8,300,000 shares at a price of $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.
How do I buy shares of Osmotica Pharmaceuticals?
Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Osmotica Pharmaceuticals' stock price today?
One share of OSMT stock can currently be purchased for approximately $4.54.
How big of a company is Osmotica Pharmaceuticals?
Osmotica Pharmaceuticals has a market capitalization of $233.90 million and generates $263.70 million in revenue each year. The company earns $-109,400,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Osmotica Pharmaceuticals employs 466 workers across the globe.View Additional Information About Osmotica Pharmaceuticals.
What is Osmotica Pharmaceuticals' official website?
How can I contact Osmotica Pharmaceuticals?
Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]
MarketBeat Community Rating for Osmotica Pharmaceuticals (NASDAQ OSMT)
| Community Ranking: | | 1.8 out of 5 ( ) |
| Outperform Votes: | | 41 (Thanks for Voting!) |
| Underperform Votes: | | 74 (Thanks for Voting!) |
| Total Votes: | | 115 |
